Variants of ST8SIA1 are associated with risk of developing multiple sclerosis by Husain, S et al.
Variants of ST8SIA1 Are Associated with Risk of
Developing Multiple Sclerosis
Seema Husain1, Cagri Yildirim-Toruner1, Justin P. Rubio2, Judith Field2, The Southern MS Genetics
Consortium2, Marvin Schwalb1, Stuart Cook3, Marcella Devoto4,5, Emilia Vitale1,6*
1 Institute of Genomic Medicine and Department of Pediatrics, UMDNJ-New Jersey Medical School, Newark, New Jersey, United States of America, 2 The Howard Florey
Institute, University of Melbourne, Parkville, Victoria, Australia, 3Department of Neuroscience UMDNJ-New Jersey Medical School, Newark, New Jersey, United States of
America, 4 The Children’s Hospital of Philadelphia, and CCEB, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America,
5Department of Experimental Medicine, University La Sapienza, Rome, Italy, 6CNR Institute of Cybernetics, Naples, Italy
Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown etiology with
both genetic and environmental factors playing a role in susceptibility. To date, the HLA DR15/DQ6 haplotype within the
major histocompatibility complex on chromosome 6p, is the strongest genetic risk factor associated with MS susceptibility.
Additional alleles of IL7 and IL2 have been identified as risk factors for MS with small effect. Here we present two
independent studies supporting an allelic association of MS with polymorphisms in the ST8SIA1 gene, located on
chromosome 12p12 and encoding ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1. The initial association was
made in a single three-generation family where a single-nucleotide polymorphism (SNP) rs4762896, was segregating
together with HLA DR15/DQ6 in MS patients. A study of 274 family trios ( affected child and both unaffected parents) from
Australia validated the association of ST8SIA1 in individuals with MS, showing transmission disequilibrium of the paternal
alleles for three additional SNPs, namely rs704219, rs2041906, and rs1558793, with p = 0.001, p = 0.01 and p= 0.01
respectively. These findings implicate ST8SIA1 as a possible novel susceptibility gene for MS.
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Introduction
Multiple sclerosis (MS) is the most common chronic inflamma-
tory disease of the central nervous system in young adults [1,2]. A
primary feature of MS is an inability of the brain to assert its
inherent restorative potential to repair damage to myelin and
oligodendrocytes. However, the severe irreversible clinical dysfunc-
tion is caused by a loss of axons that seems to occur even in early
stages of the disease [3,4,5]. The disease begins in most patients with
episodes of relapsing-remitting MS, and is often followed by a
prolonged period of clinical remission. With time and repeated
relapses, recovery is less complete and a gradual clinical progression
known as ‘‘secondary progressive MS’’ occurs. [6]
The mechanisms of demyelination and axonal injury are
heterogeneous, complex and difficult to study [5,7]. Although
the morphology of the MS lesions can provide evidence for
diagnosis, the pathophysiologies of individual plaques vary,
making the disease process difficult to define. The main challenge
in MS remains the understanding of pathological events that lead
to initiation and evolution of the disease.
While there is evidence of the involvement of environmental risk
factors, epidemiological twin and adoption studies also support a
genetic component in the etiology of the disease [8,9,10] in which
multiple interacting risk loci play a role [11]. Here we provide
strong statistical genetic evidence of the involvement of the
ST8SIA1 gene in conferring disease risk for MS. ST8SIA1 encodes
GD3 synthase, a ubiquitously expressed type II transmembrane
protein that generates GD3 ganglioside (GD3G) by catalyzing the
addition of a second sialic acid residue to its immediate precursor
GM3 [12,13,14,15] (Figure 1). Gangliosides are amphipathic
molecules composed of a ceramide lipid anchor attached to an
externally oriented oligosaccharide chain of variable length and
complexity. These lipids are the primary glycoconjugates on
neurons and carry most of the sialic acid present in the brain.
Ganglioside biosynthesis typically begins in the endoplasmic
reticulum (ER) [15] and continues in the Golgi apparatus where
resident glycosyltranferases complete the process [14,15,16]. The
functional role of GD3 synthase in important brain functions and
the identification of genetic variants associated with risk of MS
may provide a new opportunity to decipher the mechanism of
tissue injury in this disease.
Results
In a previous genome-wide linkage scan of a unique three-
generation Pennsylvania Dutch family (PD) [17], we identified an
18 cM segment on chromosome 12p12 linked to MS in association
with the HLA class II variant HLA-DR15/DQ6.
DNA sequence analysis of 10 (Table S1) of the 94 known genes
(NCBI http://www.ensembl.org) contained in the 12p12 region
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linked to MS in the Pennsylvania Dutch (PD) family [17],
identified a G/A polymorphism (rs4762896), at +29 in the intron 4
of the ST8SIA1 gene. Using high throughput sequencing analyses
we screened promoter, coding regions and associated intronic
splice junctions of the ST8SIA1 gene. The primer sequences and
the sequence information are available upon request. We
examined all seven affected as well as the 11 unaffected individuals
(Figure 2). While a number of polymorphic variants were found, in
the ST8SIA1 gene we did not identify other functional polymor-
phisms and mutations that could have been responsible for the
association and only rs4762896, clearly proved to segregate with
the affected individuals in this family. The seven patients also had
the HLA DR15/DQ6 haplotype as previously described. In
contrast, but in agreement with previous linkage analysis [17],
three (134, 133, and 124) out of the nine at-risk unaffected
individuals (Figure 2) carried the HLA DR15/DQ6 allele but did
not carry the A allele of rs4762896, while three (137, 138, and 134)
with the chromosome 12 haplotype, also had the A variant but not
HLA DR15/DQ6. The remaining three (140, 139 and 168) had
neither HLA DR15/DQ6 nor the A variant.
Given the supporting genetic data, we considered ST8SIA1 a
promising candidate risk gene for MS and initiated an indepen-
dent study for genetic association of ST8SIA1 SNPs in a large
Australian MS population. MS cases used in this study were of
North European Caucasian ancestry and selected based on the
availability of both parents. Trios offer an advantage over case
control studies since with association tests such as the transmission
disequilibrium test (TDT), results are not affected by potential bias
due to population stratification. The availability of parental
genotypes also allows testing of specific hypotheses such as parent
of origin effects, which cannot be tested in case-control samples.
We genotyped the first 209 MS trios with the previously
identified SNP located in intron 4 (rs4762896) and eight additional
SNPs (rs704219, rs2041906, rs1558793, rs2193177, rs1019332,
rs2160536, rs1861606, rs272882) that span the entire ST8SIA1
gene. Based on prior evidence of differential parental transmission
[18,19] of genetic variants in MS, we decided to test transmission
of our candidate genes SNPs separately in mothers and fathers to
the affected children.
Given the initial sample size of 209 trios, we estimated that we
had .80% power to detect an odds ratio (OR) of 1.8 or higher at
p = 0.05.
Statistical analysis of data from these samples indicated
significantly increased transmission of paternal alleles for
rs704219 (p = 0.006), rs2041906 (p= 0.004) and rs1558793
(p = 0.03). All the other SNPs had TDT p-value .0.05 (data not
Figure 1. Partial ganglioside biosynthesis pathway scheme. The three key regulatory enzymes in ganglioside biosynthesis, GM3 synthase (1),
GD3 synthase ((2) from the ST8SIA1gene), and N-acetylgalactosaminyltransferase ([3] GalNAcT) are shown. Ganglioside biosynthesis initiates with a
stepwise glycosylation of ceramide (cer) to form glucosylceramide (GlcCer) and lactosylceramide (LacCer) mediated by the enzyme ceramide
glucosyltransferase (CGT) and lactosylceramide synthase (LCS) respectively . The action of different sialyltransferases converts LacCer into
gangliosides GM3 and then GD3G. Sequential addition of N-acetylgalactosamine (GalNac), galactose and sialic acid residues generate the a-series and
b-series respectively.
doi:10.1371/journal.pone.0002653.g001
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shown). We then included 65 additional MS trios from Tasmania
genotyped for the same three SNPs. The results showed the same
trend and the combined data supported our initial observation
(p = 0.001 for rs704219, p = 0.01 for rs2041906 and p=0.01 for
rs1558793 when considering only the paternal transmission). The
SNP showing the strongest association with MS in the Australian
trio population was rs704219 or C118T, a synonymous coding
SNP in exon 5 of the ST8SIA gene. The result for rs704219 was
due to overtransmission of the minor allele T from the unaffected
fathers to offspring affected with MS (frequency of the T allele was
0.26 in transmitted, and 0.15 in un-transmitted paternal
chromosomes). The odds-ratio for risk of MS based on the
observed frequency of the T allele in transmitted and un-
transmitted paternal chromosomes was 2.02 (95% CI 1.28–3.18).
HLA DR15/DQ6 typing was available for 273 children in the
Australian trios. We tested interaction between the three SNPs
typed in the extended Australian cohorts (rs704219, rs2041906,
and rs1558793) and HLA DR15/DQ6 in two different ways. First,
we divided the trios into DR15 positive (145) and negative (128)
and repeated the TDT analysis separately in the two groups.
Results were very similar between the two groups and in
agreement with those observed in the two groups combined
although less significant as expected given the smaller sample size
(DR15-positive patients: fathers p-values: 0.01, 0.09, 0.02, mothers
p-values: 0.74, 0.23, 0.41; DR15-negative patients: fathers p-
values: 0.04, 0.06, 0.02, mothers p-values: 0.64, 0.88, 0.73). In
addition, we performed a case-only analysis of interaction by
comparing the three SNPs allele and genotype frequencies in the
two groups of patients (145 DR15 positive and 128 DR15
negative). There were no significant differences in either allele or
genotyping frequencies between the two group (all p-values
.0.05). Thus results in the Australian cohort do not show
evidence of statistical interaction between the two loci.
Finally, haplotype analysis identified a partially shared haplo-
type between the PD family and the AU trios (Table 1 and
figure 2), composed by the T allele of rs1558793 and the A allele of
rs2041906.
Discussion
The results of two independent studies reported here provide
evidence of a relationship between ST8SIA1 gene variants and the
development of MS. The first analysis identified a SNP,
rs4762896, at +29 of ST8SIA1 intron 4 in a three-generation
family of MS individuals who also carried the HLA DR15/DQ6
haplotype. This SNP is included in the linkage critical region of
the PD family. Involvement of ST8SIA1 was supported in a second
study of 274 MS trios where paternal transmission of three
additional SNPs in this gene, rs704219, rs2041906 and rs1558793,
was associated with MS (p= 0.001, p = 0.01 and p= 0.01
respectively). In the AU cohort, the increased MS risk was related
to preferential paternal transmission of the T allele for SNP
Figure 2. PD family pedigree showing the SNP haplotype and HLA DR15/DQ6 genotype. Closed symbols are the subjects with clinically
definite multiple sclerosis (CDMS) 132, 130,122,125,123,121, and clinically possible multiple sclerosis (CPMS) 131. A detailed neurological evaluation
and lab test supported the diagnosis of MS. Open symbols are the healthy subjects. The results of the SNPs analyses are reported underneath each
subject. The highlighted haplotype is composed of the same SNP alleles associated to risk of MS in the Australian trios.
doi:10.1371/journal.pone.0002653.g002
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rs704219 on 12p12. Although there are various mechanisms that
can account for paternal transmission, our results suggest that
ST8SIA1 may be an MS susceptibility gene possibly regulated by
genomic imprinting. In this regard a recent study using a
computational method for predicting the genome-wide imprinting
status of human genes was recently reported [20] and this
identified an imprinting effect between two genes, RBP5 and
ABCC9, on 12p13 and 12p12 respectively, the precise region of
the ST8SIA1 gene.
The variants described here are not rare mutations, rather they
are polymorphisms that are common in normal populations. Our
data strongly indicate that sporadic and familial MS share at least
one common genetic susceptibility and that studies of familial MS
will help our understanding of sporadic MS, as well as confirm the
genetic heterogeneity already reported [21]. Our results show that
certain ST8SIA variants are more common in MS patients from
AU and affect disease risk when paternally transmitted with an
odds-ratio of 2.02 for the minor allele (T) of rs704219.
Consequently, the effect of rs704219 on disease risk could be
greater than that previously reported for risk associated variation
in the genes for IL2RA and IL7RA (OR=1.2) [11,22,23].
In conclusion, our data support a role for the ST8SIA1 gene as a
contributing factor in MS. Our studies had the advantage of
identifying ST8SIA1 in a unique single multiplex family affected by
MS. We were then able to examine SNPs of this gene in a
collection of sporadic MS cases and their parents from Australia.
The study confirmed a role for ST8SIA1 variants in this MS
population and indicated preferential paternal transmission. While
some [24] have found a preferential transmission of MS from
affected fathers to their offspring, others [25] have not confirmed
these results. Parental effect has been recently reported as a feature
of the MHC as shown by the maternal influence in disease etiology
[26]. Our study used trios in which parents were unaffected and
prior identification of a specific risk gene variant had been made.
Outside of the immunoregulatory system, this is the first gene
extensively involved in neuronal function and membrane structure
to be implicated with MS. Having identified a specific protein and
its variants associated with MS allows a new approach towards
understanding the molecular physiopathology of the disease.
Further studies are needed to confirm and expand upon our results.
Methods
Sample collection
The blood samples were collected in preservative-free ACD tubes
under an IRB-approved protocol. DNA was extracted using the
QIAmp DNA extraction kit (QIAGEN Inc. USA). The detailed
clinical data of this family are reported elsewhere [17]. In summary
six patients had clinically definite MS (CDMS-132, 130, 122, 125,
123, 121; only one had clinically probable MS (CPMS-131) after
neurological evaluation (history, neurological exam, laboratory
testing). The phenotypic expression and temporal profile of the
disease were quite varied with regard to age of onset (24 to 33 years),
clinical course (four patients were relapsing-remitting, two were
secondary progressive, one was primary progressive) and anatom-
ical location of the lesions (cerebral [six patients], optic nerve [five],
cerebellum [five], brain stem [three], and spinal cord [six]). All had
abnormal magnetic resonance imaging (MRI) scans consistent with
MS and four of them also had abnormal cerebrospinal fluid (CSF)
profiles also consistent with MS [27].
Genomic DNAs from 209 sporadic MS trio families (affected
child, unaffected parents) from the Australian State of Victoria and
65 similar MS trios from the island State of Tasmania were
genotyped. All patients included in the study were diagnosed as
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having either clinically definite MS or laboratory-supported
definite MS or definite MS according to standard clinical criteria
[28,29,30]. Recruitment and phenotyping of the Australian MS
families were conducted by members of The Southern MS
Genetics Consortium; Trevor Kilpatrick, Simon Foote, Helmut
Butzkueven, Bruce Taylor, Niall Tubridy, Mark Marriott, Caron
Chapman, Melanie Bahlo, Terry Speed and Jim Stankovich. All
subjects were recruited according to guidelines approved by either
The Melbourne Health Human Research Ethics Committee or
the Southern Tasmanian Human Research Ethics Committee.
SNP analysis
We performed SNPs analyses in the family using a Beckman
Coulter CEQ 8000 system. The regions of interest in the ST8SIA1
gene were PCR amplified. Primer 3 software was used to design
the primers. Genomic DNA (100ng) in 25 ml PCR reaction
mixture of 1X buffer (Tris-CL, KCL, (NH4)2 SO4, 15mMMgcl2;
pH8.7), 1 X Q-solution, 200 mM of dNTP, 20pmole of each
primer and 2.5U of Taq DNA polymerase (QIAGEN Inc. USA).
The PCR mixture was denatured for 5 min at 94uC and cycled 31
times (94uC for 30 sec, 55uC for 1.15 min and 72uC for 15 sec),
followed by a 10 min extension at 72uC. Post reaction template
was cleaned up by directly adding 2 U SAP (Roche) and 1U Exo I
(MBI Fermentas), to 6ul of PCR product and incubating at 37uC
for 1 hour and 75uC for 15 min. The standard protocol of CEQ
SNP-primer extension reaction kit was used: 100ng template
DNA, 1pmole SNPs Interrogation Primers, 11 ml of SNP-primer
extension premix, to a final volume of 20 ml. The reaction mixture
was thermocycled at 96uC 10 sec, 50uC 5 sec and 72uC 30 sec for
25 cycles. Additional clean up of the extended products was done
by incubation with 1U SAP at 37uC for 1 hour and 75uC for
15 min; 0.5 ml of the purified SNP reaction to 0.5 ml size standard
80 (P/N 608395) and 39 ml of sample loading solution, to final
volume of 40 ml for each in the CEQ sample plate (P/N 609801)
and loaded. We used DNAs NA07057 and NA06990 from
CEPH/UTAH pedigree 1331 (Coriell Cell Repositories) as
normal controls. The Australian MS trio families were genotyped
using the SEQUENOM platform at The Australian Genome
Research Facility
Genes Sequences
We designed intronic primers flanking each of the exons for all
the genes located in the critical interval, using Primer3 software.
PCR amplification was performed using a QIAGEN kit and GC
Rich system (Roche) for GC rich sequences. We examined
amplified products on 1% agarose gels and purified them for
sequencing using QIAquick PCR Purification Kit (QIAGEN). We
sequenced PCR products using the CEQ Dye Terminator Cycle
Sequencing with Quick start kit (Beckman Coulter) and analyzed
them on Beckman Coulter CEQ 8000 Genetic analysis system.
We sequenced both strands of each product using DNA from all
the family members. Control DNAs C1 (NA07057) and C2
(NA06990) from CEPH/UTAH pedigree 1331 (Coriell Cell
Repositories) was sequenced as well. Analysis was done by
Chromas Sequence Analysis software.
Statistics
Association of SNP alleles with disease status was tested by
means of the transmission disequilibrium test using the software
Unphased [31]. Frequencies of transmitted and nontransmitted
alleles from parents to affected children were estimated from
parental chromosomes and used to calculate allelic odds-ratios and
their confidence intervals.
Supporting Information
Table S1 table gene’s
Found at: doi:10.1371/journal.pone.0002653.s001 (0.07 MB
DOC)
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